Telehealth company Hims & Hers (HIMS) saw a major boost in app downloads during February. According to a Top-rated analyst, Craig ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s expectations, but shares fell hard in after-hours trading ...

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

The move: Hims & Hers stock plunged by as much as 27% on Tuesday, hitting an intraday low of $37.29. The stock is down by 49% from its peak of $72.98 last week. The chart: Why: Hims & Hers said it ...

Shares of Hims & Hers Health closed down 22% on Tuesday, a day after the telehealth company released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

Still, it is inescapable that Hims & Hers growth was seen in the market as coming from its GLP-1 offerings. The drugs, called glucagon-like peptide-1, control blood sugar levels and are used to ...

News About the Weight-Loss Drugs Is Pressuring HIMS Stock Eli Lilly disclosed today that it had started selling 7.5 milligram and 10 milligram vials of Zepbound, its popular weight-loss drug, for ...

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular weight-loss drugs today. Additionally, the FDA last week hindered the ...

Hims & Hers Health reports fourth-quarter revenue of $481.14 million, beating estimates of $470.31 million. Citigroup analyst Daniel Grosslight maintains Hims & Hers with a Sell and raises the ...

Direct-to-consumer telehealth company Hims & Hers is forging ahead in the aftermath of the semaglutide shortage ending last week. Hims & Hers faces new headwinds in its weight management segment ...

Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations and gave upbeat guidance for 2025. But shares of the company dropped 19 ...